A 15 Week, Randomized, Double Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose, Safety And Efficacy Study Of Pregabalin In Adolescents (12-17 Years Old) With Fibromyalgia
Phase of Trial: Phase IV
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Pregabalin (Primary)
- Indications Fibromyalgia
- Focus Therapeutic Use
- Sponsors Pfizer
- 12 Mar 2015 Primary endpoint has not been met according to the results published in the Pfizer Media Release. (Change from baseline to week 15 in mean pain diary score)
- 12 Mar 2015 Top-line results published in the Pfizer Media Release.
- 11 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.